Evozyne logo

Evozyne, Inc.

Biotechnology

Evozyne Stock

Evozyne is a biotechnology company specializing in the creation of novel protein systems to address critical challenges in therapeutic development. Utilizing generative AI and principles of evolution, Evozyne designs high-performance, adaptive proteins for commercial applications, particularly in healthcare and environmental sustainability.

Founded: 2020

Evozyne Website

For more Evozyne stock information, or to buy or sell private shares, sign up for a MicroVentures account.

Evozyne Company Overview

Evozyne, founded by Paragon Biosciences, is dedicated to leveraging the principles of evolution and advanced computational techniques to create innovative protein systems. The company focuses on solving significant problems in human health and environmental sustainability through its cutting-edge approach to protein engineering. Evozyne's technology harnesses generative AI to simulate evolutionary processes, enabling the design of proteins with exceptional functionality and adaptability. This method allows for the exploration of vast design spaces, optimizing multiple parameters simultaneously to develop high-performance proteins. Evozyne's products include therapeutic proteins such as IgG protease enzymes and a portfolio of CRISPR gene editors, which aim to revolutionize treatments for currently untreatable diseases. Evozyne collaborates with industry giants like NVIDIA and Takeda to enhance its protein engineering capabilities. These partnerships have led to significant advancements, such as the development of therapeutic biologics with superior catalytic activity and enzymes with enhanced thermostability for CO2 capture. These innovations underscore Evozyne's commitment to accelerating the development of life-changing therapies and contributing to a healthier world.

Management Team

Mike Gamson Chief Executive Officer
Zach Serber Ph.D Chief Operating Officer
Aris Theologis Chief Business Officer
Uri Herzberg Ph.D Chief Drug Discover Officer
Rama Ranganathan Ph.D Co-Founder & Chief Strategic Officer

Funding Information